Lonafarnib: Phase IIa data

A double-blind, U.S. Phase IIa trial in 14 patients with chronic HDV infection showed that twice-daily lonafarnib reduced HDV RNA levels from baseline to day 28 by 0.73 log IU/mL at the 100 mg dose (p...